logo-loader

Sidus Space advances toward 2023 LizzieSat launch with successful completion of Critical Design Review

Published: 10:36 06 Dec 2022 EST

Sidus Space Inc - aerospace engineer conducting a Critical Design Review

Sidus Space Inc (NASDAQ:SIDU) said it has successfully completed the Critical Design Review (CDR) of its LizzieSat satellite’s integrated system architecture, which includes the LizzieSat bus with hosted payloads and sensors, the Sidus Mission Control Centre, and the launch systems required for mission success ahead of its 2023 launch.

The company said with the successful CDR, Sidus was approved to complete the final build and initiate the environments test campaign for LizzieSat’s first-generation satellites, which will support LizzieSat missions in 2023 and 2024.

It also allows Sidus to integrate approved hosted payloads and sensors into those satellites and execute mission operations from the Sidus Mission Control in Merritt Island, Florida.

READ: Sidus Space gets enhanced AS9100 certification to include engineering

The company said the successful CDR, which was conducted in accordance with NASA Procedural Requirement (NPR) 7123.1 Rev C, was a significant milestone in the development of LizzieSat.

“Following NASA-level processes gives us a high degree of confidence that our design decisions will result in the best possible mission success outcome for our satellites,” commented Sidus chief technology officer Jamie Adams.

With the flight design complete, Sidus said it will manufacture, assemble, integrate, and test leading up to the manifested 2023 launch from Cape Canaveral, Florida, on a SpaceX Falcon 9.

Sidus Space, located in Cape Canaveral, Florida, operates from a 35,000-square-foot manufacturing, assembly, integration, and testing facility focused on commercial satellite design, manufacture, launch, and data collection.

Contact the author at emily.jarvie@proactiveinvestors.com

Follow her on Twitter @emilyjjarvie

Scancell CEO on FDA breakthrough, melanoma survival data and Phase 3 plans

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L’Huillier talked with Proactive's Stephen Gunnion about the company's latest clinical and regulatory progress, including FDA RMAT designation for its lead melanoma treatment, inzitagene plasmivec (iSCIB1+), updated survival data and...

2 hours, 29 minutes ago